BRAF and metastatic malignant neoplasm in the lymph nodes: Therefore, the coexistence of the two mutations greatly exacerbates tumorigenesis, metastasis, and lymph node metastasis in PTC, and it has been demonstrated that the two-gene mutations have the following prognostic or therapeutic aggressiveness ranking for PTC patients: BRAF + TERT+ > BRAF - TERT+ > BRAF + TERT- (60).